Navigation Links
WuXi PharmaTech Announces Third Quarter 2007 Results

Third Quarter 2007 Net Income Grows 205% Year-Over-Year

SHANGHAI, China, Nov. 12 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or "the Company"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its selected unaudited financial results for the third quarter ended September 30, 2007.

Third Quarter 2007 Highlights:

-- Total net revenues increased 77.8% over the third quarter of 2006 to

$34.0 million.

-- Net revenue from laboratory services increased 59.1% over the third

quarter of 2006 to $26.7 million.

-- Net revenue from research manufacturing increased 211.8% over the

third quarter of 2006 to $7.3 million.

-- Net income increased 205.4% over the third quarter of 2006 to $8.6


-- Diluted earnings per American Depositary Share ("ADS") for the third

quarter of 2007 were $0.12. Diluted earnings per ADS excluding share-

based compensation expenses (non-GAAP) for the third quarter of 2007

were $0.15.

Commenting on the third quarter results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech commented, "I am pleased to report another quarter of strong financial and operational performance as we continue to grow our business by focusing on providing high-quality services to our customers. Our results reflect increased revenue contribution from our existing customers as well as from new customers. During the third quarter, we opened our new formulation development laboratory. In September we started the construction of our GLP (Good Laboratory Practice) drug safety eval) 1,431 (713)

Income before income taxes 8,825 2,860 22,279 5,216

Income taxes (178) (29) (507) (331)

Net income 8,647 2,831 21,772 4,885

Income (loss) attributable

to holders of ADS (Note


Basic 6,868 1,701 8,431 (38,453)

Diluted 6,898 1,701 8,431 (38,453)

Basic earnings (loss) per

ADS (Note 2) 0.15 0.05 0.27 (1.28)

Diluted earnings (loss)

per ADS (Note 2) 0.12 0.05 0.22 (1.28)

Weighted average ADS

outstanding - basic (Note

2) 44,774,893 31,132,500 30,860,969 30,131,581

Weighted average ADS

outstanding - diluted

(Note 2) 55,496,657 35,794,882 37,772,585 30,131,581

Note 2: One (1) ADS equals eight (8) ordinary shares



(in thousands of US Dollars, except per ADS data)


Three Months Ended September 30,

2007 2006

GAAP net income 8,647 2,831

Share based compensation expenses 1,475 2,492

Non-GAAP net income 10,122 5,323

Non-GAAP net income:

Attributable to holders of ADS 8,039 3,199

Attributable to holders of

preference shares 2,083 2,124

10,122 5,323

Income attributable to holders of ADS


Basic 8,039 3,199

Diluted 8,069 3,199

Basic earnings per ADS (Non-US GAAP) 0.18 0.1

Diluted earnings per ADS (Non-US

GAAP) 0.15 0.09

Weighted average ADS outstanding -

basic 44,774,893 31,132,500

Weighted average ADS outstanding -

diluted 55,496,657 35,794,882

For more information, please contact:

Investor Contact:

Dr. Hai Mi

Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd

Tel: +86-21-5046-3726


Investor Relations (US):

Mahmoud Siddig


Taylor Rafferty

Tel: +1-212-889-4350


Investor Relations (HK):

Ruby Yim

Managing Director

Taylor Rafferty

Tel: +852-3196-3712


Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350


uation center in Suzhou. In the third quarter, our interim animal facility in Suzhou has started operations. Looking forward, we will continue to invest in our capabilities and capacity to offer fully integrated drug discovery and development services to drive future long-term growth and create value to our customers and shareholders.

"Our strong financial performance over the first nine months of this year leads us to raise our full-year 2007 revenue target to the range of $131 million to $135 million, representing 87% to 93% increase over full year of 2006."

Third Quarter 2007 Unaudited Financial Results

Net Revenues.

Net revenues grew 77.8% to $34.0 million in the third quarter of 2007, compared to $19.2 million for the third quarter of 2006, primarily attributable to increased business volume and expansion of services and capacities. Net revenues from laboratory services increased by 59.1% to $26.7 million in the third quarter of 2007 from $16.8 million in the third quarter of 2006. The revenue increase in laboratory services is primarily driven by the strong growth of our core discovery chemistry services. Net revenues from research manufacturing increased by 211.8% to $7.3 million in the third quarter of 2007 from $2.3 million in the third quarter of 2006, primarily attributable to expanded collaborations with our customers.

Gross Profit.

Gross profit increased 76.4% to $16.0 million in the third quarter of 2007, compared to $9.1 million in the third quarter of 2006. The cost of revenues for laboratory services and research manufacturing were $13.8 million and $4.2 million, respectively, in the third quarter of 2007, compared to $8.0 million and $2.1 million in the third quarter of 2006, respectively. Overall gross margin was 47.0% in the third quarter of 2007, slightly down from 47.4% in the third quarter of 2006.

Laboratory service gross margin was 48.2% in the third quarter of 2007, decreased by 4.1% comparing to the same period of 2006, primarily due to an increase in depreciation as a result of expanded laboratory facilities to support future business growth and the appreciation of Chinese Yuan.

Research manufacturing gross margin improved significantly from 12.2% of the third quarter 2006 to 42.4% of the third quarter of 2007 as we started to achieve economy of scale as more and larger research manufacturing projects were carried out in 2007 compared to 2006.

Operating Expenses.

Operating expenses increased 38.1% to $8.5 million in the third quarter of 2007 from $6.2 million in the third quarter of 2006. The increase of these expenses was a result of the business growth. However, operating expenses as a percentage of total net revenues decreased to 25.0% in the third quarter of 2007 from 32.1% in the third quarter of 2006 as a result of cost efficiency.

Share-Based Compensation Expenses.

The Company's share-based compensation expenses, which were allocated to related expense line items, decreased from $2.5 million in the third quarter of 2006 to $1.5 million in the third quarter of 2007.

Net Income.

Net income increased by 205.4% to $8.6 million for the third quarter of 2007 from $2.8 million for the third quarter of 2006. Net profit margin increased to 25.4% in the third quarter of 2007 from 14.8% in the third quarter of 2006. Non-GAAP net income excluding share-based compensation expenses for the third quarter of 2007 increased by 90.2% to $10.1 million, compared to the non-GAAP net income of $5.3 million from third quarter of 2006. Diluted earnings per ADS was $0.12 and diluted earnings per ADS excluding share-based compensation expenses (non-GAAP) was $0.15 for the third quarter of 2007.

Conference Call

Following the earnings announcement, WuXi PharmaTech's senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Tuesday, November 13, 2007 to discuss its 2007 third quarter financial results and recent business activities. The conference call may be accessed by calling (US) +1-866-316-1369 / (UK) +0-800-051-7166 / (HK) +800-965-503. A telephone replay will be available shortly after the call until December 12, 2007 at (US) +1-888-203-1112/ (UK) +0-808-101-1153 / (HK) +800-901-108, Passcode: 7947278.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and research manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit:

Use of Non-GAAP Financial Measures

WuXi PharmaTech has provided the third quarters of 2006 and 2007 net income and earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing the Company's financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. The Company expects to provide net income and earnings per ADS on a non-GAAP basis using a consistent method on a quarterly basis going forward.

Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, WuXi PharmaTech's anticipated operating results for 2007, our continued efforts to build our capabilities and expand our services, anticipated success of our newly opened formulation laboratory, the design of our new GLP drug safety evaluation center in Suzhou, and our interim animal facility in Suzhou. These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among the factors that could cause WuXi PharmaTech's actual results to differ from what we currently anticipates may include our limited operating history; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of its large customers, which could significantly harm our cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our prospectus filed with the Securities and Exchange Commission on August 9, 2007, and is available on the Securities and Exchange Commission's website at For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 11 of our prospectus. Our actual results of operations for the third quarter of 2007 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, WuXi PharmaTech undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.



(in thousands of US Dollars, except ADS data and par value data)

September 30, December 31,

2007 2006

(derived from


(unaudited) financials)


Current assets:

Cash and cash equivalents 212,774 9,683

Restricted cash 2,133 2,067

Accounts receivables, net 16,441 12,589

Inventories 11,753 9,617

Prepaid expenses and other

current assets 11,915 2,696

Total current assets 255,016 36,652

Non-current assets:

Property, plant and

equipment, net 63,807 42,776

Intangible assets, net 993 628

Land use rights, net 5,050 4,643

Other non-current assets 1,948 992

Total non-current assets 71,798 49,039

Total assets 326,814 85,691

Liabilities, mezzanine equity and

shareholders' equity (deficit)

Current liabilities:

Short-term bank borrowings,

current 1,331 9,604

Accounts payables 6,391 9,259

Accrued expenses 14,740 5,012

Deferred revenue 19,900 2,619

Other tax payable 3,815 2,343

Other current liabilities 3,080 1,757

Total current

liabilities: 49,257 30,594

Non-current liabilities:

Long-term debt, excluding

current portion 3,994 5,763

Advanced subsidies 1,154 1,027

Convertible notes 40,988 0

Deferred tax liabilities 122 129

Total non-current

liabilities 46,258 6,919

Total liabilities 95,515 37,513

Mezzanine equity 0 49,106

Shareholders' equity (deficit):

Ordinary shares (Note 1),

($0.02 par value,

550,000,000 authorized,

249,060,000 and

492,226,776 issued and

outstanding as of December

31, 2006 and September 30,

2007, respectively) 9,845 4,981

Additional paid-in capital 286,548 33,075

Accumulated deficit (69,433) (40,173)

Accumulated other

comprehensive income 4,339 1,549

Treasury stock 0 (360)

Total shareholders'

equity (deficit) 231,299 (928)

Total liabilities,

mezzanine equity and

shareholders' equity

(deficit) 326,814 85,691

Note 1: Eight (8) ordinary shares are equal to one (1) ADS




(in thousands of US dollars, except ADS data and per ADS data)

(Unaudited )

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Net revenues:

Laboratory services 26,744 16,808 73,539 38,102

Manufacturing 7,305 2,343 24,572 8,993

Total net revenues 34,049 19,151 98,111 47,095

Cost of revenues:

Laboratory services (13,843) (8,024) (36,499) (17,329)

Manufacturing (4,206) (2,056) (14,666) (8,257)

Total cost of revenues (18,049) (10,080) (51,165) (25,586)

Gross Profit 16,000 9,071 46,946 21,509

Operating expenses:

Selling and marketing

expenses (468) (554) (1,683) (1,198)

General and administrative

expenses (8,032) (5,599) (24,415) (14,382)

Total operating expenses (8,500) (6,153) (26,098) (15,580)

Operating income 7,500 2,918 20,848 5,929

Other income (expenses),


Other income (expenses),

net (9) 141 842 108

Interest income

(expenses), net 1,334 (199) 589 (821)

Total other income

(expenses), net 1,325 (58

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
(Date:11/25/2015)... ... ... The holiday season is jam-packed with family dinners, parties ... is of the utmost importance. Whether you are cooking at home for the ... try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the ... loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and ... hair, without the need for surgery, prescription pills, or topical foams. , “Capillus272™ ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 /PRNewswire/ ... --> Juntendo universitetssjukhus ser potential att ... av magnetresonansbilder (MR-bilder) för patienter med ... tecknat ett forskningsavtal med SyntheticMR AB för ... kliniska forskningsprojekt på sjukhuset. Med SyMRI kan ...
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
Breaking Medicine Technology: